Showing results (91-100 of 111) with videos related to
Sort By:
Pageof 12
Multiple Sclerosis and Related Disorders|January 5, 2023
Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohortSimon Englund, Marie Kierkegaard, Joachim Burman, et al.Annals of Neurology|June 26, 2024
COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with RituximabFredrik Piehl, Peter Alping, Suvi Virtanen, et al.Annals of Clinical and Translational Neurology|August 22, 2022
COVID-19 clinical outcomes and DMT of MS patients and population-based controlsElisa Longinetti, Hannah Bower, Kyla A McKay, et al.Journal of the Neurological Sciences|June 19, 2022
MIF in the cerebrospinal fluid is decreased during relapsing-remitting while increased in secondary progressive multiple sclerosisSimone Hjæresen, Tobias Sejbaek, Markus Axelsson, et al.Journal of Neurology, Neurosurgery, and Psychiatry|September 25, 2023
Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort studyThomas Silfverberg, Christina Zjukovskaja, Per Ljungman, et al.Therapeutic Advances in Neurological Disorders|January 31, 2022
Smouldering multiple sclerosis: the 'real MS'Gavin Giovannoni, Veronica Popescu, Jens Wuerfel, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|November 2, 2019
Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studiesBart Van Wijmeersch, Barry A Singer, Aaron Boster, et al.Journal of Neurology|March 4, 2021
The levels of the serine protease HTRA1 in cerebrospinal fluid correlate with progression and disability in multiple sclerosisSimone Hjæresen, Tobias Sejbaek, Marcus Axelsson, et al.Neurology and Therapy|June 24, 2021
Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS StudiesSamuel F Hunter, Rany A Aburashed, Raed Alroughani, et al.Multiple Sclerosis and Related Disorders|June 17, 2023
Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registriesTereza Hrnciarova, Jiri Drahota, Tim Spelman, et al.Pageof 12